Bone-Adhesive Thermoresponsive Hydrogel Drug Delivery Composition
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current drug delivery systems for oral diseases and periodontal diseases face challenges such as systemic side effects, poor solubility, and rapid clearance of drugs like GSK3β inhibitors and statins, limiting their effectiveness and safety when administered systemically, and hydrogels like Poloxamer 407 have poor bone-adhesion and mechanical properties, reducing bioavailability.
Innovation Solution
A modified poloxamer, such as pyrophosphorylated Pluronic F127, is used to create a thermoresponsive hydrogel that adheres to bones or teeth, enhancing drug solubility and release kinetics, and includes therapeutic agents like GSK3β inhibitors and statins for targeted local delivery.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If systemic medication is used to treat oral diseases, then therapeutic coverage is improved, but side effects and drug resistance increase
Solution Approach 1:
The patent applies local quality by designing a hydrogel delivery system that releases drugs specifically at the periodontal disease site. The modified poloxamer hydrogel adheres to oral tissues and provides localized drug release, ensuring therapeutic action is concentrated where needed while minimizing systemic exposure and associated side effects
2Reliability
If GSK3β inhibitors and statins are administered systemically, then therapeutic effects are improved, but solubility and clearance issues limit effectiveness
Solution Approach 1:
The patent uses the modified poloxamer hydrogel as an intermediary carrier system. This hydrogel mediates drug delivery by solubilizing poorly soluble compounds like GSK3β inhibitors and statins, protecting them from rapid clearance, and facilitating their transport to the periodontal tissue where they exert therapeutic effects
3Ease of operation
If conventional hydrogels like Poloxamer 407 are used for drug delivery, then ease of administration is improved, but bone-adhesion and mechanical properties are poor
Solution Approach 1:
The patent creates a composite material by chemically modifying poloxamer 407 with pyrophosphate groups. This composite structure combines the ease of hydrogel administration with enhanced bone-adhesion properties. The pyrophosphate modification enables specific binding to hydroxyapatite in bone and tooth tissues, while the hydrogel matrix maintains its gelation and drug delivery capabilities
4Object-affected harmful factors
If drugs are delivered locally to periodontal pockets, then systemic toxicity is reduced, but poor solubility and rapid clearance remain challenges
Solution Approach 1:
The patent implements continuity of useful action through the hydrogel's sustained drug release mechanism. The modified poloxamer hydrogel maintains drug reservoirs at the periodontal site and releases medications continuously over time, counteracting rapid clearance and ensuring adequate drug concentrations are maintained locally while minimizing systemic exposure
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The modified hydrogel effectively adheres to oral tissues, providing sustained release of drugs over several days with improved bioavailability, reducing systemic toxicity and enhancing therapeutic effects on periodontal tissues.
Implementation Method 1
the poloxamer is modified to be capable of adhering to a surface of bones or teeth
Implementation Method 2
a thermoresponsive hydrogel that adheres to bones or teeth
Data Source
AI summary
Disclosed is a hydrogel drug delivery composition comprising a therapeutic agent and a poloxamer, wherein the poloxamer is modified to be capable of adhering to a surface of bones or teeth, and wherein the poloxamer is modified by pyrophosphate, bisphosphonates, acidic peptides or tetracycline and its derivatives.